HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Newman, S. B. Articles by Raghavan, V. Search for Related Content PubMed PubMed Citation Articles by Newman, S. B. Articles by Raghavan, V.

The Journal of Thoracic and Cardiovascular Surgery, Vol 86, 180-185, Copyright © 1983 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Treatment of modified Stage II (T1 N1 M0, T2 N1 M0) non-small cell bronchogenic carcinoma. A combined modality approach

SB Newman, TR DeMeester, HM Golomb, PC Hoffman, AG Little and V Raghavan

Twenty patients with postsurgical, modified Stage II (T2 N1 M0, T1 N1 M0) non-small cell bronchogenic carcinoma were seen between 1974 and 1981 and were evaluated in a retrospective manner. Fifteen patients had T2 N1 M0 lesions, while 5 patients had T1 N1 M0 disease. Eight patients were treated with surgical resection alone, of whom seven had died, with a median survival of 12.0 months. Four patients received surgical resection and postoperative radiation therapy, of whom two have died, with a median survival not reached at 37 months. Eight patients were treated with surgical resection, radiation therapy, and adjuvant chemotherapy including cyclophosphamide (C), doxorubicin (A), methotrexate (M), and procarbazine (P). Six patients are alive and free of disease, with a median survival not yet reached at 72 months. There is a significant survival advantage for the 12 patients treated with combined modality therapy (surgical resection + radiation therapy; surgical resection + radiation therapy + chemotherapy) compared to the eight patients treated with SR alone (p less than 0.01), and for the eight patients receiving chemotherapy versus the 12 patients who did not (p less than 0.01). In spite of thorough clinical and surgical staging, patients with T1 and T2 primary tumors with N1 disease have a high relapse rate, predominantly in metastatic sites. Adjuvant radiation therapy and chemotherapy appear to benefit these patients with modified Stage II non-small cell bronchogenic carcinoma.

This article has been cited by other articles:

				J. H. Park, Y. M. Shim, H. J. Baek, M.-S. Kim, D. H. Choe, K.-J. Cho, C.-T. Lee, and J. I. Zo Postoperative adjuvant therapy for stage II non-small-cell lung cancer Ann. Thorac. Surg., November 1, 1999; 68(5): 1821 - 1826. [Abstract] [Full Text] [PDF]

				I. Yoshino, R. Nakanishi, T. Osaki, M. Takenoyama, S. Taga, T. Hanagiri, and K. Yasumoto Unfavorable Prognosis of Patients With Stage II Non-small Cell Lung Cancer Associated With Macroscopic Nodal Metastases Chest, July 1, 1999; 116(1): 144 - 149. [Abstract] [Full Text] [PDF]

				T. Yano, H. Yokoyama, T. Inoue, H. Asoh, K. Tayama, and Y. Ichinose Surgical results and prognostic factors of pathologic N1 disease in non-small-cell carcinoma of the lungSignificance of N1 level: lobar or hilar nodes J. Thorac. Cardiovasc. Surg., June 1, 1994; 107(6): 1398 - 1402. [Abstract] [Full Text]

				N. Martini, M. E. Burt, M. S. Bains, P. M. McCormack, V. W. Rusch, and R. J. Ginsberg Survival after resection of stage II non-small cell lung cancer Ann. Thorac. Surg., September 1, 1992; 54(3): 460 - 466. [Abstract] [PDF]

				K. Nakahara, K. Ohno, J. Hashimoto, S. Miyoshi, H. Maeda, A. Matsumura, T. Mizuta, A. Akashi, K. Nakagawa, and Y. Kawashima Prediction of Postoperative Respiratory Failure in Patients Undergoing Lung Resection for Lung Cancer Ann. Thorac. Surg., November 1, 1988; 46(5): 549 - 552. [Abstract] [PDF]

				E. C. Holmes Carcinoma of the Lung Ann. Thorac. Surg., May 1, 1988; 45(5): 582 - 582. [PDF]